ロード中...
Data from the US and UK cystic fibrosis registries support disease modification by CFTR modulation with ivacaftor
BACKGROUND: Ivacaftor is the first cystic fibrosis transmembrane conductance regulator (CFTR) modulator demonstrating clinical benefit in patients with cystic fibrosis (CF). As ivacaftor is intended for chronic, lifelong use, understanding long-term effects is important for patients and healthcare p...
保存先:
| 出版年: | Thorax |
|---|---|
| 主要な著者: | , , , , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
BMJ Publishing Group
2018
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6204955/ https://ncbi.nlm.nih.gov/pubmed/29748252 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/thoraxjnl-2017-210394 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|